The latest evidence of efficacy and safety of an interleukin-5 inhibitor, mepolizumab, has improved the therapy of refractory or recurrent eosinophilic granulomatosis with polyangiitis (EGPA) [12]. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.